Novo Nordisk already sells the only GLP-1 shot approved for fatty-liver inflammation. It still paid $4.7 billion for a drug built for the stage Wegovy cannot reach: cirrhosis.
At the American Association for the Study of Liver Diseases (AASLD) meeting in Denver, November 5–9, one dataset after another drew the same line. Weight-loss drugs clear fat and inflammation from the liver. Scar tissue moves far more slowly.
The first US approval for compensated MASH cirrhosis will go to Madrigal's Rezdiffra or an FGF21 drug, not to a GLP-1, and Rezdiffra's MAESTRO-NASH OUTCOMES trial will hit its primary endpoint when it reads out in late 2027.
That call is wrong if semaglutide or survodutide files for, or wins, a cirrhosis label before the end of Q1 2028, or if the Rezdiffra outcomes trial fails.
01 · GLP-1s clear the inflammation, not the scars
MASH runs on two tracks. One is disease activity: inflammation and ballooning of liver cells. The other is fibrosis, the scarring that climbs from F1 to F4 cirrhosis. The FDA scores them separately.
Wegovy won its MASH label in August 2025 on the ESSENCE trial. At week 72, 63% of patients on semaglutide saw MASH resolve versus 34% on placebo. Fibrosis improved by at least one stage in 37% versus 22%. Measured against placebo, the activity gap was about twice the size of the fibrosis gap.
Boehringer Ingelheim's survodutide made the pattern sharper at AASLD. Arun Sanyal of Virginia Commonwealth University split 116 treated patients from the phase 2 trial by weight loss. Among those who lost at least 15%, 78.4% saw MASH resolve and 64.9% saw fibrosis improve. Among those who lost under 5%, the figures were 36.8% and 47.4%. Activity endpoints climbed steeply with weight loss; fibrosis barely tilted.
Zydus's saroglitazar, presented as a late-breaker on November 8, showed the same shape. In the 189-patient EVIDENCES-X trial, 39.1% on the 4 mg dose saw MASH resolve versus 13.7% on placebo. Fibrosis improvement, at 34.8% versus 24.6%, was not statistically significant.
Hepatologist Winston Dunn described the clinical side. Patients screened for MASH trials now arrive with lower activity but more advanced fibrosis, which he tied to GLP-1 use. A median of roughly a year on the drugs is enough to lower inflammation scores but not to reverse scarring.
The clearest precedent is Novo's own. A 2023 phase 2 trial of semaglutide in compensated cirrhosis, published in The Lancet Gastroenterology & Hepatology, found fibrosis improved in 11% of treated patients and 29% on placebo.

Fig. 1 · Across three drugs, the bar for fibrosis improvement sits well below the bar for MASH resolution.
02 · The deal terms put the upside on cirrhosis
The clause most coverage skipped is the contingent value right.
In October 2025 Novo agreed to buy Akero for $54 a share in cash. The extra $6 a share, about $0.5 billion, pays out only if efruxifermin wins US approval for compensated MASH cirrhosis. Roche's 89bio deal three weeks earlier carried a CVR of up to $6 a share; one milestone is the first sale of pegozafermin to F4 patients before March 31, 2030.
Neither buyer tied its upside to the F2–F3 patients Wegovy already treats.
Novo's own AASLD slate explains why. Its three Wegovy analyses at the meeting all excluded cirrhosis, and Wegovy's US label does not cover it. Efruxifermin, an FGF21 analog, filled that gap in the phase 2 SYMMETRY study: after 96 weeks in F4 patients, fibrosis improved in 29% versus 11% on placebo, the mirror image of the 2023 semaglutide result.
GSK presented the designs of two phase 3 programs for its monthly FGF21 drug efimosfermin at AASLD: ZENITH in F2–F3 and NEBULA in compensated cirrhosis. Boehringer runs a dedicated cirrhosis phase 3, LIVERAGE-Cirrhosis. Three of the four big pharmas own the same class of molecule, and all four have written cirrhosis into a trial or a deal.

Fig. 2 · Novo, Roche and GSK hold FGF21 assets; Boehringer holds a dual agonist. Each points at F4.
03 · Rezdiffra grew alongside the GLP-1s
When Wegovy won its MASH label, the obvious loser looked like Madrigal, whose Rezdiffra became the first approved MASH drug in March 2024.
The opposite happened. On November 3 Madrigal reported third-quarter Rezdiffra sales of $431.3 million, up 50% year over year, with more than 55,850 patients on therapy and quarterly net income of $55.4 million against a $114.2 million loss a year earlier.
Real-world data released on November 5 show why the two drugs did not cannibalize each other: up to 53% of Rezdiffra patients also take a GLP-1. Hepatologists use the shot for weight and glucose and add a liver-directed drug on top.
Chief executive Bill Sibold put the cirrhosis goal in one line: "Our objective in F4c is clear: be first and best." The MAESTRO-NASH OUTCOMES trial in compensated cirrhosis is due in late 2027.
The FDA's bar on fibrosis is high. In June 2023 Intercept received a second rejection for obeticholic acid in pre-cirrhotic fibrosis and then left MASH. That history is why the stronger bets are the programs built around hard outcomes.
04 · How the business changes
Patients will be sorted by stage. People with F1–F3 disease get a GLP-1 first; Novo has filed oral Wegovy for MASH in the US and expects a decision in the first half of 2027.
The premium market sits at the back end. Madrigal cites a 42-fold higher risk of liver-related death once patients progress to cirrhosis. Those patients need a drug that reverses scarring, and payers will price it differently.
Diagnostics become the gate. Dunn presented SMART-MASH, a cirrhosis screen that mixes elastography, ELF blood tests and routine labs and found about a third more cirrhosis than the Agile 4 score.
Portfolio shape matters. Novo can pair its own GLP-1 with its own FGF21. Roche and GSK will lean on combination with someone else's GLP-1. Madrigal has already shown that a single liver drug can grow next to the shots.
The calendar is set: Novo expects efruxifermin phase 3 safety results this quarter and F2–F3 histology in the second half of 2027; Rezdiffra's cirrhosis outcomes follow at year-end.

Fig. 3 · Patient flow by fibrosis stage, with F4 still waiting for a dedicated label.
05 · What would prove this wrong
Time is the strongest counterargument. Dunn's patients had about a year of GLP-1 exposure, and ESSENCE has so far reported only its first part. If longer treatment slowly reverses scarring, GLP-1s could move from F2 down to F4.
FGF21 drugs are injectables with small phase 2 datasets, and effects often shrink in larger trials. The FDA also wants clinical outcomes in cirrhosis, not just biopsies, which lengthens timelines.
The checks are clear: the Rezdiffra outcomes readout, the efruxifermin phase 3 histology, and whether any GLP-1 maker files for cirrhosis first.
06 · Taiwan: seven million patients, and only the front-end drug
Yu Ming-lung, president of the Taiwan Liver Research Society, said in June that 33.3% of Taiwanese adults have metabolic fatty liver, above the 30.5% global average, or roughly seven million people.
The same briefing described a 34-year-old real-estate agent who gained about 24 kg in six months and saw liver enzymes above 300. Today his new-drug option is a GLP-1.
Taiwan's patients arrive late: 40% to 52% of MASH patients already have moderate-to-severe fibrosis at diagnosis, and about a fifth of liver cancers are linked to fatty liver. Liver cancer remains Taiwan's second-deadliest cancer in the 2025 death statistics.
Physicians at the briefing said Taiwan approved a GLP-1 for MASH in March 2026. That puts Taiwan where the US, Europe and Japan are: a drug for the front half of the disease, and a wait for the next round of phase 3 data for the back half.
This article is industry and company analysis, not investment or medical advice.

References
- Liver Drug Saroglitazar Nearly Triples Placebo's MASH Resolution Rate · Tech Times · 2026-11-08 · https://www.techtimes.com/articles/330261/20261108/liver-drug-saroglitazar-nearly-triples-placebos-mash-resolution-rate-zydus-trial-shows.htm
- Survodutide Improves MASH Liver Endpoints Across Weight Loss Categories · HCPLive · 2026-11-07 · https://www.hcplive.com/view/survodutide-improves-mash-liver-endpoints-across-weight-loss-categories
- GLP-1s Lower MASH Activity but Not Fibrosis: Winston Dunn · AJMC · 2026-11-07 · https://www.ajmc.com/view/glp-1s-lower-mash-activity-but-not-fibrosis-winston-dunn-md-faasld
- Madrigal Announces New Real-World Data at AASLD 2026 · GlobeNewswire · 2026-11-05 · https://www.globenewswire.com/news-release/2026/11/05/3396655/0/en/madrigal-announces-new-real-world-data-at-aasld-2026-demonstrating-improvements-in-liver-stiffness-and-cardiometabolic-health-markers-with-rezdiffra.html
- Madrigal Third Quarter 2026 Financial Results · SEC · 2026-11-03 · https://www.sec.gov/Archives/edgar/data/0001157601/000162828026069093/exhibit991-93026earningspr.htm
- GSK showcases progress in liver portfolio at AASLD 2026 · GSK · 2026-11-05 · https://www.gsk.com/en-gb/media/press-releases/gsk-showcases-progress-in-liver-portfolio-at-aasld-2026/
- Novo to present new liver data at AASLD 2026 · PR Newswire · 2026-10-28 · https://www.prnewswire.com/news-releases/novo-to-present-new-liver-data-across-wegovy-2-4-mg-and-investigational-efruxifermin-at-the-liver-meeting-aasld-2026--302922177.html
- Novo Nordisk Financial Report Q3 2026 · SEC · 2026-11-04 · https://www.sec.gov/Archives/edgar/data/0000353278/000162828026069805/caq32026.htm
- Novo Nordisk to acquire Akero Therapeutics · Novo Nordisk · 2025-10-09 · https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916433
- Roche becomes MASH player via $3.5B deal for 89bio · Fierce Biotech · 2025-09-18 · https://www.fiercebiotech.com/biotech/roche-becomes-mash-player-35b-deal-89bio-and-its-phase-3-drug
- FDA Approves Semaglutide (Wegovy) for Noncirrhotic MASH · HCPLive · 2025-08-15 · https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash
- Semaglutide Shows Lack of Improvement in Liver Fibrosis · HCPLive · 2023-03-20 · https://www.hcplive.com/view/semaglutide-well-tolerated-shows-lack-improvement-liver-fibrosis
- Intercept Complete Response Letter for Obeticholic Acid · SEC · 2023-06-22 · https://www.sec.gov/Archives/edgar/data/1270073/000110465923073909/tm2319514d1_ex99-1.htm
- Fatty liver affects one in three Taiwanese adults · Asia Pacific News Network (yam) · 2026-06-09 · https://n.yam.com/Article/20260609146222
- 2025 Cause of Death Statistics · Ministry of Health and Welfare, Taiwan · 2026-06-22 · https://mohw.gov.tw/cp-16-86970-1.html
Share this analysis
Send this article to readers who follow biotech, company strategy, and capital-market signals.
Cite this article
For decks, research notes, or media references, cite Drugnews with the canonical article URL.
Drugnews Editorial Team. "Weight-loss shots stop short of cirrhosis, so Novo bought a $4.7B fix." Drugnews, Nov 13, 2026. https://drugnews.com.tw/articles/2026-11-13-mash-cirrhosis-fgf21-novo-akero-glp1-fibrosis-gap-en.html